comprehensive -WSS

comprehensive

author：leisure time 2025-10-06 07:54:32 - browse：654

Today, if you want to know what scary family health secrets lay buried in your DNA or get screened for a lurking cancer, you have a lot of options. Laboratories have developed more than 75,000 genetic tests, with about 10 new ones entering the market daily. By the end of 2019, more than 26 million Americans had had their DNA decoded to some degree or another. Since then, that number has surely grown.

But this testing frenzy would have been inconceivable just 10 years ago. In part, that’s because the technology back then was so expensive. More importantly, until 2013, it was common practice for gene-hunting academics and companies to lock up their discoveries with DNA patents, effectively carving up the human genome into mini-monopolies. That year, the U.S. Supreme Court threw a bomb into the biotech world when it took up a landmark case that pitted cancer survivors and the American Civil Liberties Union against a diagnostics company called Myriad Genetics, which had obtained exclusive patents on the cancer-causing BRCA genes and made billions of dollars selling tests for them.

A new book called “The Genome Defense,” written by University of Utah science and technology law expert Jorge Contreras and being published Oct. 26, provides a front-row seat to the courtroom drama that would upend three decades of federal intellectual property law and chart a new course toward balancing corporate profits with the rights of all people to the information written into their DNA.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： NFL doctors' conflicts of interest could endanger players, report says

entertainment

hotspot

WSS

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Doctors are clamoring for more clarity on Paxlovid prescribing

Kansas bar where gunfire wounded 9 last month closes permanently

Change Healthcare cyberattack prompts Medicare loan program

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

Doctors are clamoring for more clarity on Paxlovid prescribing

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The drug industry has found itself all alone in Washington

The high cost of giving birth even with insurance

It was time to plan for my old age. If only I could stop crying

In Memoriam: Notable people who died in 2023

Feed a cold, starve a fever? Here’s what science says

Medical records are filled with copy

Kansas bar where gunfire wounded 9 last month closes permanently

explore

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Tuberculosis patients need more than just free medication

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Sweden knocks USA out of World Cup in penalty kicks

Doctors are clamoring for more clarity on Paxlovid prescribing

With psoriasis trial ahead, Alumis raises $259 million

entertainment

entertainment

hotspot

leisure time